Table 1.
Demographic and clinical characteristics of the patients undergoing intestinal resection n (%)
| Variables | Number of patients |
| (n = 260) | |
| SEX | |
| Male | 187 (71.9) |
| Female | 73 (28.1) |
| Follow-up period, month | 101 (12-193) |
| Age at diagnosis | 23 (12-74) |
| Age at 1st operation | 28 (15-74) |
| Age at 2nd operation | 34 (22-59) |
| Montreal classification | |
| Age at diagnosis, yr | |
| A1 ( ≤ 16) | 25 (9.6) |
| A2 (17-40) | 215 (82.7) |
| A3 ( > 40) | 20 (7.7) |
| Location | |
| L1 (Terminal ileum) | 113 (43.5) |
| L2 (Colon) | 38 (14.6) |
| L3 (Ileocolon) | 107 (41.2) |
| L4 (Isolated upper disease) | 2 (0.8) |
| Behavior | |
| B1 (Inflammatory) | 6 (2.3) |
| B2 (Stricturing) | 80 (30.8) |
| B3 (Penetrating) | 174 (66.9) |
| Family history (Crohn's disease) | 7 (2.7) |
| Presence of extraintestinal manifestation | 20 (7.7) |
| Perianal disease | |
| at diagnosis | 122 (46.9) |
| after 1st operation | 62 (23.8) |
| History of smoking | 70 (26.9) |
| Current smoker | 12 (4.6) |
| Ex-smoker | 58 (22.3) |
| Non-smoker | 190 (73.1) |
| Preoperative use of medication | |
| Anti-TNF | 27 (10.4) |
| 5-ASA | 223 (85.8) |
| Steroid | 147 (56.5) |
| Immunomodulator1 | 128 (49.2) |
| Antibiotics2 | 128 (49.2) |
| Malignancy | 163 (62.7) |
| Colorectal cancer | 3 (1.2) |
| Lung cancer | 1 (0.4) |
1
Use of azathioprine/6-mercaptopurine or methotrexate;
2
Ciprofloxacin or metronidazole. EIM: Extraintestinal manifestation; 5-ASA: Aminosalicylates; TNF: Tumor necrosis factor.